Ferroptosis drove CCl4-induced mouse models of ALI
As shown in Fig. 1A, typical histopathological changes of ALI were observed microscopically in the CCl4-administered mouse livers and compared with those in the PBS and oil groups (left and middle), including diffuse hepatic necrosis. To investigate the contribution of ferroptotic cell death in CCl4-induced ALI, we performed real-time PCR analysis of putative molecular markers of ferroptosis, which showed that CCl4 treatment induced robust increases in the mRNA levels of liver prostaglandin-endoperoxide synthase 2 (Ptgs2), 15-LOX, 12-LOX, and 5-LOX (Fig. 1B). Next, we measured lipid peroxidation in living liver cells by flow cytometry using the C11-BODIPY581/591 fluorescent probe, a canonical index of ferroptosis. CCl4 significantly increased the lipid-ROS levels in the mouse livers of the CCl4-treated group compared with the PBS and oil groups (Fig. 1C). The release of oxidized lipid mediators is a reported characteristic of ferroptosis[26]. Membranes with arachidonic acid enrichment may facilitate ferroptosis by releasing arachidonic acid metabolites (hydroxyeicosatetraenoic acid) during cell death. The levels of 20-hydroxyeicosatetraenoic acid (HETE), 15(R)-HETE, 15(S)-HETE, 12-HETE, 11-HETE, 8-HETE, and 18-HETE were increased in the livers of mice 48 h after CCl4 injection (Fig. 1D). These findings suggest that ferroptosis is a crucial driver of CCl4-induced liver injury and mortality in mice.
MSC transplantation alleviated CCl4-induced ferroptosis in ALI
Oxidative stress-induced excessive accumulation of lipid hydroperoxides ultimately results in ferroptosis. We showed that MSC treatment dramatically alleviated CCl4-induced ALI due to its immunomodulatory function[7]. Moreover, MSC play important roles in reducing oxidative stress[27]. Thus, we hypothesize that MSC may have a protective role against ferroptosis by promoting lipid-ROS scavenging in CCl4-induced ALI. Histopathological staining indicated that hepatic necrosis was dramatically improved following administration of MSC and ferrostatin-1 compared with the CCl4 group, indicating the effect of MSC against CCl4-induced ferroptosis in ALI (Fig. 2A). Compared with the CCl4, we observed significant decreases in the mRNA levels of Ptgs2, 12-LOX, 5-LOX, and 15-LOX, classic biomarkers of ferroptosis, in the MSC and Fer-1 groups (Fig. 2B). MSC treatment also significantly reduced the accumulation of CCl4-induced lipid hydroperoxides in the liver (Fig. 2C). Interestingly, according to the mRNA levels of liver Ptgs2 and LOXs, and lipid peroxidation in living cells, it is plausible that MSC and ferrostatin-1 have comparable effects on protection against ferroptosis. Compared with Fer-1, MSCs had a similar effect on protection against liver damage, as evidenced by C11-BODIPY581/591 probe staining (Fig. 2C). The decreases in the Ptgs2, 12-LOX, 5-LOX, and 15-LOX mRNA levels were similar between the MSC and Fer-1 groups (Fig. 2B). It is worth noting that LOXs (and particularly 15-LOX) have been reported as essential regulators of ferroptotic cell death as they contribute to the cellular pool of lipid hydroperoxides[28, 29]. Moreover, the increased levels of 20-hydroxyeicosatetraenoic acid (HETE), 15(R)-HETE, 15(S)-HETE, 12-HETE, 11-HETE, 8-HETE, and 18-HETE induced by CCl4 was abrogated by MSC and Fer-1 treatment (Fig. 2D). These results suggest that the potential ability of MSC to downregulate peroxidation contributes to lipid-ROS reduction and inhibits the progression of ferroptosis.
The xCT protein level was downregulated in CCl4-induced ALI but upregulated following MSC treatment invivoandin vitro
Next, we established an acute hepatocyte injury model to detect the mechanisms underlying xCT regulation in ALI treated with MSC in vitro. On days 1, 2, 3, and 7, we detected a dramatic decrease in cell viability using the Cell Counting Kit-8 when the concentration of CCl4 increased to 10 mM (Fig. 3A). To investigate the role of the xCT protein in the CCl4-induced acute hepatocyte injury model, we performed WB analysis to assess the protein expression levels according to the concentration and time of CCl4 treatment. The xCT protein level was significantly downregulated at a CCl4 concentration of 10 mM (Fig. 3B). Furthermore, without active intervention, the xCT protein level decreased at 24 h after incubation with CCl4 and remained low at 48 and 72 h (Fig. 3C).
Based on the above hepatocyte model, co-culturing experiments were performed to investigate the effects of MSC on damaged hepatocytes. As shown in Fig. 3D, AST and ALT levels were significantly increased in the CCl4 group but dramatically reduced after MSC co-culture. We speculate that MSC have a protective effect in ALI via the paracrine pathway. Next, to ascertain whether co-culture with MSC also rescues the CCl4-induced decrease in the xCT protein level in primary hepatocytes, WB analysis was performed. Interestingly, similar to the in vivo findings, the xCT protein level was reduced in the CCl4 group compared with the PBS group but was restored by MSC co-culture (Fig. 3E). These results suggest that a paracrine factor mediates the regulation of xCT protein levels to facilitate the protective effects of MSC against ferroptosis.
MSC-derived exosomes inhibited ferroptosis in CCl4-induced ALIin vitro
To further examine the role of MSC in ALI, we ascertained the levels of ROS and MDA. As shown in Fig. 4A, MSC co-culture with hepatocytes reduced the upregulation of ROS induced by CCl4. In addition, CCl4 induced a dramatic increase in MDA, a marker of ferroptosis, similar to erastin, while co-culture with MSC downregulated the increased MDA level, similar to Fer-1, in hepatocytes (Fig. 4B). These data indicate that MSC exert protective effects via paracrine mechanisms in ALI. Recent studies have shown that MSC produce exosomes, which can ameliorate tissue injury via the delivery of its DNA, miRNA, and protein contents[30–32]. Therefore, we extracted and identified exosomes from MSC conditioned medium. We used refrigerated transmission electron microscopy (Fig. 4C) and WB analysis (Supplementary Fig. S1D) to characterize vesicles recovered from the MSC-conditioned medium by differential ultracentrifugation and identified 30–100 nm vesicles that were morphologically similar to exosomes, which expressed the CD63 and CD81 exosomal markers. To determine whether hepatocytes can internalize MSC-Exo, we labeled exosomes with green lipophilic fluorescent dye (PKH67), and they were subsequently co-cultured with CCl4-induced injury hepatocytes. The hepatocytes exhibited high uptake efficiency, as indicated by the green fluorescent signal (Fig. 4D). Furthermore, after 24 h incubation with PKH67-labeled exosomes, more MSC-Exo aggregated on the cell membrane in CCl4-induced injured hepatocytes, suggesting that the MSC-Exo exert anti-ferroptotic effects by fusing with the recipient cell membrane or interacting with proteins on the cell membrane. Next, we measured the lipid peroxidation of the primary hepatocytes with CCl4-induced injury after MSC-Exo treatment. Similar to erastin, CCl4 induced significant upregulation of lipid-ROS level, while MSC-Exo treatment decreased the upregulated level of lipid-ROS, similar to Fer-1 treatment (Fig. 4E). Moreover, CCl4 induced a dramatic increase in the MDA level, similar to erastin, while MSC-Exo reduced the increased MDA level, similar to Fer-1, in hepatocytes (Fig. 4F). This data suggested that MSC-derived exosomes inhibited ferroptosis in CCl4-induced ALI in vitro.
MSC-derived exosomes inhibited ferroptosis in CCl4-induced ALI invivo
Having shown that MSC-Exo inhibited ferroptosis in CCl4-induced liver injury in vitro, we investigated the effects of MSC-Exo in CCl4-induced ferroptosis in vivo. Interestingly, MSC-Exo also ameliorated hepatic necrosis and downregulated the increased ALT/AST levels induced by CCl4 in ALI, which is consistent with the protective effects of MSC (Fig. 5A and B). In addition, measurement of MDA levels and real-time PCR analysis of molecular markers of ferroptosis showed that MSC-Exo treatment significantly downregulated MDA and liver Ptgs2, 15-LOX, 12-LOX, and 5-LOX mRNA levels induced by CCl4 (Fig. 5C and D). These findings suggest that MSC-Exo also inhibit ferroptosis in CCl4-induced liver injury in vivo.
MSC-Exo protect against ferroptosis via stabilization of xCT in ALI
We investigated the underlying mechanisms of the MSC-Exo-mediated protective effects against CCl4-induced ferroptosis. Accumulating evidence indicates that the stability of xCT, which is the functional subunit of a glutamate–cysteine transporter that resides on the cell membrane, is modulated by CD44v8–10[20, 33]. CD44 is a cell surface marker of MSCs[7] and a critical molecule inducing firm adhesion between MSC and injured liver tissues, which mediate the recruitment of MSC to CCl4-induced liver injury[34]. Moreover, we detected CD44 protein both in MSC and MSC-derived exosomes (Supplementary Fig. S1D). Therefore, we hypothesized that the CD44–xCT axis is functionally related to the anti-ferroptotic effects of MSC-Exo treatment. As shown in Fig. 6A, xCT protein levels in acute injured hepatocytes treated with 0, 20, 40, 80, and 160 µg MSC-Exo were measured by WB analysis. Interestingly, the exosome-induced recovery of xCT protein was accompanied by upregulation of CD44 and OTUB1, key regulators of xCT function and CD44-mediated effects in ferroptosis, in a dose-dependent manner. OTUB1, an ovarian tumor deubiquitinase family member, was previously reported to directly interact with and regulate xCT stability[35]. Furthermore, CCl4 administration increased the ubiquitination of xCT, while MSC-Exo treatment downregulated the ubiquitination of xCT (Fig. 6B). These data suggest that CCl4-induced ubiquitination abolished the stabilization of xCT, leading to a downregulated level of xCT in ALI. However, MSC-Exo treatment promotes the stabilization of xCT by reducing its ubiquitination, resulting in upregulation of xCT in ALI.
To determine the mechanisms by which MSC-Exo exerts protective effects against ferroptosis, we performed immunofluorescence and co-immunoprecipitation analyses. Immunofluorescence analysis suggested that CD44 and xCT were co-expressed and increased in ALI after MSC-Exo treatment compared with the CCl4 and PBS groups (Fig. 6C). Next, to measure the interaction under physiological conditions, we performed co-immunoprecipitation analysis targeting endogenous proteins expressed in liver tissues of ALI after MSC-Exo treatment. As shown in Fig. 6D, the endogenous CD44 and OTUB1 proteins were co-precipitated by a xCT-specific antibody, while endogenous xCT was co-precipitated by a CD44-specific and OTUB1-specific antibody, respectively (Fig. 6E and F). Thus, we further speculated that MSC-Exo treatment promotes increases in CD44 and OTUB1 proteins and stabilizes xCT by directly interacting with and reducing its ubiquitination in CCl4-induced ALI.
MSC-Exo in the circulation localized more readily in the liver in CCl4-induced ALI
Next, we hypothesized that exosomes participate in tissue crosstalk during MSC-Exo treatment, resulting in exosome uptake in the recipient tissues. To determine the biodistribution of MSC-Exo after entering the circulation during treatment, we isolated MSC-Exo from MSC-conditioned medium and labeled them with lipophilic carbocyanine DiR. Next, the labeled MSC-Exo were intravenously administered via the tail to ALI mice, which were subjected to whole-body intravital imaging. In vivo fluorescent imaging showed that DiR-labeled MSC-Exo targeted the injured and normal livers at 6 h post-injection. There was also more fluorescence in ALI mice compared with the PBS and oil groups (Fig. 7A), indicating that MSC-Exo in circulation were more likely to aggregate in damaged livers. We performed fluorescent imaging of the lung, heart, kidney, liver, and spleen of ALI mice treated with DiR-labeled MSC-Exo to confirm this. As shown in Fig. 7B, the experiments in mice receiving labeled MSC-Exo showed significantly higher fluorescent signals in the liver compared with other organs, suggesting that MSC-Exo in circulation localized more readily in the liver in ALI mice. Neutralizing antibodies against CD44 reduced MSC-Exo targeting to the diseased liver by 30.85% (P < 0.05) (Fig. 7C). These results indicated that the effect of MSC-Exo on protection against ferroptosis was associated with the function of CD44.